IOncology

At the 2024 European Lung Cancer Congress (ELCC) held in Paris, Oncology Frontier conducted an exclusive interview with Professor Wenxiu Yao from Sichuan Cancer Hospital. Professor Yao provided in-depth commentary on the latest research presented at the congress regarding antibody-drug conjugates (ADCs) in the treatment of lung cancer.

The 2025 European Lung Cancer Congress (ELCC) officially opened on March 26 in Paris, France. On the very first day, during the Proffered Paper Session 1, the highly anticipated final overall survival (OS) results from the MARIPOSA study (Abstract 4O) were presented.Oncology Frontier invited Professor Rui Ma of Liaoning Cancer Hospital to provide an in-depth expert analysis of the updated data and its implications for clinical practice.

At the 2025 European Lung Cancer Congress (ELCC), new data from the ORCHARD study were presented, highlighting the potential of osimertinib in combination with Dato-DXd as a post-progression strategy following first-line osimertinib treatment in patients with EGFR-mutant non-small cell lung cancer (NSCLC). This marks the first public release of efficacy and safety findings for this combination in the treatment of EGFR-TKI resistant NSCLC.

At the 2025 European Lung Cancer Congress (ELCC), the team led by Professor Lin Wu from the Hunan Cancer Hospital, Xiangya Hospital, Central South University, presented long-term follow-up data on ASK120067 (rezivertinib) in patients with locally advanced or metastatic EGFR T790M-mutant non-small cell lung cancer (NSCLC). Oncology Frontier invited Professor Wu to comment on the key findings and clinical implications of the study for our readers.

The recently concluded 2025 European Lung Cancer Congress (ELCC) spotlighted several key clinical topics and unveiled new research with strong translational potential. Oncology Frontier invited Professor Wei Zhang of Shanghai Chest Hospital, Shanghai Jiao Tong University for an in-depth interview, where she shared expert insights on the congress's most impactful themes and dissected the scientific highlights shaping the future of lung cancer treatment.

Dr. Shahnaz Sultan led the multidisciplinary panel behind the AGA Living Clinical Practice Guideline on Computer-Aided Detection–Assisted Colonoscopy, published in April 2025 in Gastroenterology.This guideline addresses one of the most…

A patient-level pooled analysis combining the DEBBRAH and TUXEDO-1 trials along with the DFCI/Duke/MDACC cohort, published in ESMO Open (January 3, 2025), demonstrated clinically meaningful intracranial efficacy of trastuzumab deruxtecan…

Published on December 18, 2024 in the Journal of Clinical Oncology, the phase III postMONARCH trial presents compelling data on abemaciclib + fulvestrant for patients with advanced breast cancer who…

A phase II clinical study on the sequential use of Adebrelimab combined with chemotherapy followed by thoracic radiotherapy has garnered widespread attention at ASCO 2024, particularly for its impact on the treatment of extensive-stage small cell lung cancer (ES-SCLC).The results are striking: the regimen significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to existing standards, while maintaining a favorable safety profile. Most notably, this strategy set a new survival benchmark for first-line immunotherapy in SCLC, demonstrating the value of integrating immune checkpoint inhibition with thoracic radiotherapy. This innovative approach represents a major step forward in SCLC treatment and offers renewed hope for patients battling this aggressive disease. In light of these findings, Oncology Frontier invited Academician Jinming Yu to share insights into the study design, key outcomes, and its clinical implications. The following is a summary of his expert commentary.

At the 2025 China National Breast Cancer Conference, CSCO President and Director of Shandong Cancer Hospital, Academician Jinming Yu, delivered a keynote address titled “Precision Integration of Radiotherapy and Immunotherapy in Breast Cancer.” His presentation explored not only the evolving role of radiotherapy in breast cancer treatment but also offered key insights into strengthening China’s scientific innovation capacity in oncology. Following the session, Oncology Frontier invited Academician Yu to share his perspectives on the clinical application of radiotherapy in breast cancer, strategies for advancing China's global competitiveness in oncology, and his long-standing commitment to cultivating young academic talent.